Completed

RIC-AMDThe Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

RIC

+ Aspirin

DeviceDrug
Who is being recruted

Arterial Occlusive Diseases+8

+ Brain Diseases

+ Cardiovascular Diseases

From 18 to 60 Years
+11 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: July 2019
See protocol details

Summary

Principal SponsorCapital Medical University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 15, 2019

Actual date on which the first participant was enrolled.

There are a series of symptoms such as ischemic stroke、transient ischemic attack 、hemorrhagic stroke、headache 、seizure and so on in moyamoya disease. Nowadays, revascularization is the only effective way for ischemic MMD while controversial for hemorrhagic MMD patients. Surgical complications including hyperperfusion syndrome, cerebral infarction or bleeding often occurred postoperatively. There is no effective conservative treatment for MMD up to now. Remote ischemic conditioning is Remote ischemic conditioning (RIC) is a noninvasive and easy-to-use neuroprotective strategy, and it has potential effects on preventing ischemia reperfusion injury and ischemic infarction.This study was to explore the safety and efficacy of remote ischemic conditioning on adult MMD patients.

Official TitleThe Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease
NCT04012268
Principal SponsorCapital Medical University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

30 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Arterial Occlusive DiseasesBrain DiseasesCardiovascular DiseasesCarotid Artery DiseasesCentral Nervous System DiseasesCerebral Arterial DiseasesCerebrovascular DisordersMoyamoya DiseaseNervous System DiseasesVascular DiseasesIntracranial Arterial Diseases

Criteria

4 inclusion criteria required to participate
Age: 18-60 years
All of the patients underwent digital subtraction angiography (DSA) and met the current diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012.
mRs≤3
Informed consent obtained from patient or acceptable patient's surrogate.
7 exclusion criteria prevent from participating
Patients with acute ischemic or hemorrhagic stroke within 3 months.
Severe hepatic or renal dysfunction.
Severe hemostatic disorder or severe coagulation dysfunction.
Severe cardiac diseases.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs. They will also accept medication treatment by professional neurologists.

Group II

Patients allocated to Medication group will accept medication treatment by professional neurologists.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Xuanwu Hospital, Capital Medical University

Beijing, ChinaOpen Xuanwu Hospital, Capital Medical University in Google Maps
CompletedOne Study Center
RIC-AMD | The Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease | PatLynk